Citigroup’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-4
| Closed | -$20 | – | 5871 |
|
|
2024
Q1 | $20 | Sell |
4
-94
| -96% | -$584 | ﹤0.01% | 5547 |
|
|
2023
Q4 | $661 | Sell |
98
-27
| -22% | -$237 | ﹤0.01% | 5489 |
|
|
2023
Q3 | $1.14K | Sell |
125
-2
| -2% | -$40 | ﹤0.01% | 5078 |
|
|
2023
Q2 | $2.69K | Buy |
127
+12
| +10% | +$370 | ﹤0.01% | 5251 |
|
|
2023
Q1 | $3.08K | Sell |
115
-275
| -71% | -$12.8K | ﹤0.01% | 5033 |
|
|
2022
Q4 | $13.8K | Buy |
390
+250
| +179% | +$30K | ﹤0.01% | 4728 |
|
|
2022
Q3 | $32K | Sell |
140
-123
| -47% | -$30.2K | ﹤0.01% | 4575 |
|
|
2022
Q2 | $50K | Buy |
263
+60
| +30% | +$12.1K | ﹤0.01% | 4542 |
|
|
2022
Q1 | $50K | Sell |
203
-279
| -58% | -$44.1K | ﹤0.01% | 4734 |
|
|
2021
Q4 | $75K | Buy |
482
+151
| +46% | +$29.2K | ﹤0.01% | 4883 |
|
|
2021
Q3 | $66K | Buy |
331
+70
| +27% | +$16.6K | ﹤0.01% | 4598 |
|
|
2021
Q2 | $66K | Sell |
261
-12
| -4% | -$3K | ﹤0.01% | 4683 |
|
|
2021
Q1 | $72K | Sell |
273
-1,871
| -87% | -$589K | ﹤0.01% | 4523 |
|
|
2020
Q4 | $791K | Buy |
2,144
+143
| +7% | +$41K | ﹤0.01% | 3776 |
|
|
2020
Q3 | $489K | Sell |
2,001
-18
| -0.9% | -$5.6K | ﹤0.01% | 3863 |
|
|
2020
Q2 | $581K | Sell |
2,019
-99
| -5% | -$29.2K | ﹤0.01% | 4096 |
|
|
2020
Q1 | $432K | Buy |
2,118
+1,894
| +846% | +$604K | ﹤0.01% | 4007 |
|
|
2019
Q4 | $100K | Buy |
224
+159
| +245% | +$56.4K | ﹤0.01% | 5777 |
|
|
2019
Q3 | $19K | Sell |
65
-177
| -73% | -$57.5K | ﹤0.01% | 6775 |
|
|
2019
Q2 | $76K | Sell |
242
-697
| -74% | -$241K | ﹤0.01% | 6120 |
|
|
2019
Q1 | $394K | Buy |
939
+935
| +23,375% | +$375K | ﹤0.01% | 4440 |
|
|
2018
Q4 | $1K | Hold |
4
| – | – | ﹤0.01% | 7609 |
|
|
2018
Q3 | $2K | Hold |
4
| – | – | ﹤0.01% | 7625 |
|
|
2018
Q2 | $2K | Hold |
4
| – | – | ﹤0.01% | 7483 |
|
|
2018
Q1 | $1K | Hold |
4
| – | – | ﹤0.01% | 7481 |
|
|
2017
Q4 | $2K | Hold |
4
| – | – | ﹤0.01% | 7413 |
|
|
2017
Q3 | $1K | Hold |
4
| – | – | ﹤0.01% | 7170 |
|
|
2017
Q2 | $1K | Sell |
4
-6
| -60% | -$1.36K | ﹤0.01% | 7227 |
|
|
2017
Q1 | $4K | Buy |
10
+5
| +100% | +$1.72K | ﹤0.01% | 6875 |
|
|
2016
Q4 | $2K | Buy |
5
+1
| +25% | +$366 | ﹤0.01% | 7075 |
|
|
2016
Q3 | $2K | Sell |
4
-14
| -78% | -$7.14K | ﹤0.01% | 6937 |
|
|
2016
Q2 | $11K | Buy |
18
+12
| +200% | +$7.29K | ﹤0.01% | 6511 |
|
|
2016
Q1 | $3K | Buy |
6
+2
| +50% | +$996 | ﹤0.01% | 7157 |
|
|
2015
Q4 | $3K | Sell |
4
-8
| -67% | -$4.53K | ﹤0.01% | 7215 |
|
|
2015
Q3 | $6K | Sell |
12
-6
| -33% | -$3.18K | ﹤0.01% | 6670 |
|
|
2015
Q2 | $10K | Buy |
18
+7
| +64% | +$19.4K | ﹤0.01% | 6477 |
|
|
2015
Q1 | $96K | Hold |
11
| – | – | ﹤0.01% | 5057 |
|
|
2014
Q4 | $97K | Buy |
+11
| New | +$63.8K | ﹤0.01% | 5252 |
|
|
2014
Q2 | – | Hold |
0
| – | -$2K | – | 7360 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 6800 |
|
Other funds holding EIGR
Citigroup's EIGR Position: Q2 2024 in Review
Citigroup sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2024, closing a stake of 4 shares — an estimated $20 sold.
Citigroup first reported a position in EIGR in Q4 2014 and held it in 38 quarters. The position peaked at $791K in Q4 2020. 2 funds tracked by Wall St. Rank hold EIGR as of Q2 2024.
- Citigroup reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- Citigroup sold 4 Eiger BioPharmaceuticals, Inc. shares in Q2 2024, an estimated $20.
- Citigroup first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2014 and held it in 38 quarters.
- Citigroup's Eiger BioPharmaceuticals, Inc. position peaked at $791K in Q4 2020.
- 2 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2024.
Based on Citigroup's 13F filing for Q2 2024, filed 12 Aug 2024.